Patents by Inventor James R. Corte

James R. Corte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20230390249
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: August 22, 2023
    Publication date: December 7, 2023
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists
    Publication number: 20230339884
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: May 22, 2023
    Publication date: October 26, 2023
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
    Patent number: 11697646
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: July 11, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • MACROCYCLES AS FACTOR XIA INHIBITORS
    Publication number: 20230058729
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: October 4, 2021
    Publication date: February 23, 2023
    Inventors: James R. CORTE, Tianan FANG, Carl P. DECICCO, Donald J.P. PINTO, Karen A. ROSSI, Zilun HU, Yoon JEON, Mimi L. QUAN, Joanne M. SMALLHEER, Yufeng WANG, Wu YANG
  • TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20220324829
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: April 7, 2021
    Publication date: October 13, 2022
    Inventors: YAN SHI, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20220249443
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: April 12, 2022
    Publication date: August 11, 2022
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Cyclohexyl acid pyrazole azoles as LPA antagonists
    Patent number: 11352345
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: June 7, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Hao Zhang, Jun Li, Tianan Fang, James R. Corte
  • Cyclohexyl acid triazole azoles as LPA antagonists
    Patent number: 11319315
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 3, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Li, Tianan Fang, James R. Corte, Jun Shi, Hao Zhang, Lawrence J. Kennedy, Shiwei Tao
  • Cyclohexyl acid triazole azines as LPA antagonists
    Patent number: 11267800
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng, Jun Shi, Shiwei Tao, James R. Corte, Tianan Fang, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Sutjano Jusuf
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20220041601
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 15, 2021
    Publication date: February 10, 2022
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • RADIOLIGANDS FOR IMAGING THE LPA1 RECEPTOR
    Publication number: 20210379210
    Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists of Formula (I) or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein, which are useful for the quantitative imaging of LPA1 receptors in mammals.
    Type: Application
    Filed: October 14, 2019
    Publication date: December 9, 2021
    Inventors: Peter Tai Wah Cheng, James R. Corte, David J. Donnelly, Joonyoung Kim, Jun Shi, Shiwei Tao, Tritin Tran
  • Macrocycles as factor XIA inhibitors
    Patent number: 11136327
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
    Publication number: 20210244711
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 12, 2021
    Inventors: PETER TAI WAH CHENG, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS
    Publication number: 20210230143
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: July 29, 2021
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng, Jun Shi, Shiwei Tao, James R. Corte, Tianan Fang, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Sutjano Jusuf
  • Pyrimidinones as factor XIA inhibitors
    Patent number: 11053247
    Abstract: The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS
    Publication number: 20210163470
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 3, 2021
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Li, Tianan Fang, James R. Corte, Jun Shi, Hao Zhang, Lawrence J. Kennedy, Shiwei Tao
  • Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
    Patent number: 11008300
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: 11007180
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS
    Publication number: 20210078982
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 18, 2021
    Inventors: Yan Shi, Peter Tai Wah Cheng, Hao Zhang, Jun Li, Tianan Fang, James R. Corte
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: RE49352
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: January 3, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Badu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf